Maureen Dubreuil, MD, MSc.

Associate Professor, Medicine

Maureen Dubreuil
617.638.5180
maureen.dubreuil@bmc.org
650 Albany St Evans Biomed Research Ctr
View full profile at BUMC

Biography

Dr. Dubreuil is a rheumatologist in Boston, specializing in spondyloarthritis. She works within the Rheumatology section at Chobanian and Avedisian School of Medicine, where her research focuses on comorbidities and pharmacoepidemiology of spondyloarthritis. Dr. Dubreuil’s research has been funded by numerous competitive grants from funders including the NIH, private foundations and industry. Some highlights of Dr. Dubreuil’s work includes:
1. Discovery of two key protective effects of TNF inhibitors against fractures and cardiovascular events in spondyloarthritis
2. Finding that a common nonsteroidal anti-inflammatory drug is associated with 3 times the risk of heart attack among people with spondyloarthritis
3. Development of the first North American guidelines for referral of adults at increased risk of having spondyloarthritis to a rheumatologist

In addition to her research, Dr. Dubreuil is a member of the leading international organizations for spondyloarthritis research. She serves on the Executive Committee of the Board of Directors for the Spondyloarthritis Research and Treatment Network, and on the Medical Advisory Board for the Spondylitis Association of America. She is a site investigator for the international CLASSIC study in spondyloarthritis. Dr. Dubreuil is the Director of Research Training for the Rheumatology Fellowship program at Boston Medical Center.

Dr. Dubreuil cares for people with rheumatic conditions at Boston Medical Center and the VA Boston Healthcare System. Dr. Dubreuil’s patients say the following about her:
“Dr. Dubreuil is a very caring and knowledgeable doctor and it’s always a pleasure to be seen by her.”
“I am very satisfied with the care I have received. My provider and the support staff is very professional, caring and concerned. I would recommend to anyone.”
“Dr. Dubreuil is a gem and I feel so lucky to have her!”

Other Positions

  • Member, Arthritis & Autoimmune Diseases Research Center, Boston University
  • VA Boston Healthcare System

Websites

Education

  • University of Connecticut School of Medicine, MD
  • Boston University School of Public Health, MSc
  • Rochester Institute of Technology, BS

Publications

  • Published on 4/1/2025

    Ferrandiz-Espadin R, Rabasa G, Gasman S, McGinley B, Stovall R, Jafarzadeh SR, Liew JW, Dubreuil M. Disparities in Time to Diagnosis of Radiographic Axial Spondyloarthritis. J Rheumatol. 2025 Apr 01; 52(4):344-351. PMID: 39486857.

    Read at: PubMed
  • Published on 2/12/2025

    Sendaydiego X, Gold LS, Dubreuil M, Andrews JS, Reid P, Liew DFL, Goulabchand R, Hughes GC, Sparks JA, Jarvik JG, Singh S, Liew JW, Singh N. Comparative safety of biologic and targeted synthetic disease-modifying anti-rheumatic drugs for cardiovascular outcomes in rheumatoid arthritis. Rheumatology (Oxford). 2025 Feb 12. PMID: 39936579.

    Read at: PubMed
  • Published on 2/1/2025

    Jinno S, Onishi A, Hattori S, Dubreuil M, Ueda Y, Nishimura K, Okano T, Yamada H, Yamamoto W, Murata K, Onizawa H, Ebina K, Maeda Y, Son Y, Amuro H, Hara R, Hata K, Shiba H, Katayama M, Watanabe R, Hashimoto M, Saegusa J. Comparison of retention of biologics in Japanese patients with elderly-onset rheumatoid arthritis-the ANSWER cohort study. Rheumatology (Oxford). 2025 Feb 01; 64(2):509-516. PMID: 38317442.

    Read at: PubMed
  • Published on 1/1/2025

    Navarro-Compán V, Rudwaleit M, Dubreuil M, Magrey M, Marzo-Ortega H, Mease PJ, Walsh JA, Dougados M, de la Loge C, Fleurinck C, Massow U, Vaux T, Taieb V, Deodhar A. Improved Pain, Morning Stiffness, and Fatigue With Bimekizumab in Axial Spondyloarthritis: Results From the Phase III BE MOBILE Studies. J Rheumatol. 2025 Jan 01; 52(1):23-32. PMID: 39406403.

    Read at: PubMed
  • Published on 12/16/2024

    Driscoll D, George N, Peloquin C, Jafarzadeh SR, Liew JW, Dubreuil M. Association of Therapies for Axial Spondyloarthritis on the Risk of Hip and Spine Fractures. Arthritis Rheumatol. 2024 Dec 16. PMID: 39679763.

    Read at: PubMed
  • Published on 12/1/2024

    Dubreuil M, Ferucci ED, El-Gabalawy H, Hasni S, Williams EM. Enhancing Equity in Clinical Research: A Multifaceted Proposal for Spondyloarthritis. J Rheumatol. 2024 Dec 01; 51(12):1247-1253. PMID: 39448246.

    Read at: PubMed
  • Published on 12/1/2024

    Colbert RA, Carroll E, Dubreuil M, Gensler LS, Haroon N, Howard R, Ogdie AR, Shafer C, Weiss PF, Kuhn KA. Prologue: Spondyloarthritis Unmet Research Needs Conference IV. J Rheumatol. 2024 Dec 01; 51(12):1226-1228. PMID: 39448249.

    Read at: PubMed
  • Published on 11/4/2024

    Sendaydiego X, Gold LS, Dubreuil M, Andrews JS, Reid P, Liew DFL, Goulabchand R, Singh AG, Hughes GC, Pioro M, Sparks JA, Jarvik JG, Singh S, Liew JW, Singh N. Use of Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drugs and Cancer Risk. JAMA Netw Open. 2024 Nov 04; 7(11):e2446336. PMID: 39565623.

    Read at: PubMed
  • Published on 6/4/2024

    Dubreuil M, Navarro-Compán V, Boonen A, Gaffney K, Gensler LS, de la Loge C, Vaux T, Fleurinck C, Massow U, Taieb V, Mørup MF, Deodhar A, Rudwaleit M. Improved physical functioning, sleep, work productivity and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: results from two phase 3 studies. RMD Open. 2024 Jun 04; 10(2). PMID: 38834351.

    Read at: PubMed
  • Published on 6/2/2024

    Liew JW, Treu T, Park Y, Ferguson JM, Rosser MA, Ho YL, Gagnon DR, Stovall R, Monach P, Heckbert SR, Gensler LS, Liao KP, Dubreuil M. The association of TNF inhibitor use with incident cardiovascular events in radiographic axial spondyloarthritis. Semin Arthritis Rheum. 2024 Oct; 68:152482. PMID: 38865875.

    Read at: PubMed

View 60 more publications: View full profile at BUMC

View all profiles